Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
Mediterr J Hematol Infect Dis
.
2019 Jul 1;11(1):e2019045.
doi: 10.4084/MJHID.2019.045.
eCollection 2019.
Authors
Ioannis Kotsianidis
1
,
Sotirios G Papageorgiou
2
,
Vassiliki Pappa
2
,
Athanasios G Galanopoulos
3
,
Nora-Athina Viniou
4
,
Theodoros P Vassilakopoulos
5
,
Menelaos Papoutselis
1
,
George Vrachiolias
1
,
Vasileios Papadopoulos
1
,
Panagiotis T Diamantopoulos
3
,
Dimitris Tsokanas
4
,
Alexandra Kourakli
6
,
Argiris Symeonidis
6
Affiliations
1
Department of Hematology, Democritus University of Thrace Medical School; Greece.
2
Second Department of Internal Medicine, Hematology Unit, Attikon University General Hospital, Athens, Greece.
3
Department of Clinical Hematology, G. Gennimatas Hospital, Athens, Greece.
4
Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
5
Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
6
Department of Internal Medicine, University Hospital of Patras, Rio, Greece.
PMID:
31308921
PMCID:
PMC6613620
DOI:
10.4084/MJHID.2019.045
No abstract available
Keywords:
Azacytidine; MDS; Prognostic models.